References
- Alalwani SM, Sierigk J, Herr C et al. (2010) The antimicrobial peptide LL-37 modulates the inflammatory and host defense response of human neutrophils. Eur J Immunol 40:1118–1126.
https://doi.org/10.1002/eji.200939275 - Alexandre-Ramos DS, Silva-Carvalho AÉ, Lacerda MG et al. (2018) LL-37 treatment on human peripheral blood mononuclear cells modulates immune response and promotes regulatory T-cells generation. Biomed Pharmacother 108:1584–1590.
https://doi.org/10.1016/j.biopha.2018.10.014 - Al-Sabagh FS, Ghaima KK (2022) Synergistic effect of antimicrobial peptide LL-37 and ciprofloxacin against multidrug resistant Pseudomonas aeruginosa isolated from burn infections. Iraqi J Biotechnol 21:32–38.
- Amrein K, Schnedl C, Holl A et al. (2014) Effect of high-dose vitamin D3 on hospital length of stay in critically ill patients with vitamin D deficiency: The VITdAL-ICU randomized clinical trial. JAMA 312: 1520–1530.
https://doi.org/10.1001/jama.2014.13204 - Ashoor TM, Abd Elazim AEH, Mustafa ZAE et al. (2024) Outcomes of high-dose versus low-dose vitamin D on prognosis of sepsis requiring mechanical ventilation: A Randomized Controlled Trial. J Intensive Care Med 39:1012–1022.
https://doi.org/10.1177/08850666241250319 - Bandurska K, Berdowska A, Barczyńska-Felusiak R et al. (2015) Unique features of human cathelicidin LL-37. Biofactors 41:289–300.
https://doi.org/10.1002/biof.1225 - Barbeiro DF, Barbeiro HV, Zampieri FG et al. (2013) Cathelicidin LL-37 bloodstream surveillance is down regulated during septic shock. Microbes Infect 15:342–346.
https://doi.org/10.1016/j.micinf.2013.01.001 - Berkestedt I, Herwald H, Ljunggren L et al. (2010) Elevated plasma levels of antimicrobial polypeptides in patients with severe sepsis. J Innate Immun 2:478–482.
https://doi.org/10.1159/000317036 - Berkestedt I, Nelson A, Bodelsson M (2008) Endogenous antimicrobial peptide LL-37 induces human vasodilatation. Br J Anaesth 100:803–809.
https://doi.org/10.1093/bja/aen074 - Bowdish DM, Davidson DJ, Hancock R (2005) A re-evaluation of the role of host defence peptides in mammalian immunity. Curr Protein Pept Sci 6:35–51.
https://doi.org/10.2174/1389203053027494 - Bucki R, Byfield FJ, Janmey PA (2007) Release of the antimicrobial peptide LL-37 from DNA/F-actin bundles in cystic fibrosis sputum. Eur Respir J 29:624–632.
https://doi.org/10.1183/09031936.00080806 - Bucki R, Leszczyńska K, Namiot A et al. (2010) Cathelicidin LL-37: A multitask antimicrobial peptide. Arch Immunol Ther Exp 58:15–25.
https://doi.org/10.1007/s00005-009-0057-2 - Byfield FJ, Wen Q, Leszczynska K et al. (2011) Cathelicidin LL-37 peptide regulates endothelial cell stiffness and endothelial barrier permeability. Am J Physiol Cell Physiol 300:C105–112.
https://doi.org/10.1152/ajpcell.00158.2010 - Castillo JA, Giraldo DM, Smit JM et al. (2022) Vitamin D-induced LL-37 modulates innate immune responses of human primary macrophages during DENV-2 infection. Pathog Dis 80:ftac014.
https://doi.org/10.1093/femspd/ftac014 - Chen CI, Schaller-Bals S, Paul KP et al. (2004) Beta-defensins and LL-37 in bronchoalveolar lavage fluid of patients with cystic fibrosis. J Cyst Fibros 3:45–50.
https://doi.org/10.1016/j.jcf.2003.12.008 - Cheung GYC, Bae JS, Liu R et al. (2021) Bacterial virulence plays a crucial role in MRSA sepsis. PLoS Pathog 17:e1009369.
https://doi.org/10.1371/journal.ppat.1009369 - Chinipardaz Z, Zhong JM, Yang S (2022) Regulation of LL-37 in bone and periodontium regeneration. Life 12:1533.
https://doi.org/10.3390/life12101533 - Cirioni O, Ghiselli R, Tomasinsig L et al. (2008) Efficacy of LL-37 and granulocyte colony-stimulating factor in a neutropenic murine sepsis due to Pseudomonas aeruginosa. Shock 30:443–448.
https://doi.org/10.1097/SHK.0b013e31816d2269 - Cirioni O, Giacometti A, Ghiselli R et al. (2006) LL-37 protects rats against lethal sepsis caused by gram-negative bacteria. Antimicrob Agents Chemother 50:1672–1679.
https://doi.org/10.1128/aac.50.5.1672-1679.2006 - Coorens M, Scheenstra MR, Veldhuizen EJ et al. (2017) Interspecies cathelicidin comparison reveals divergence in antimicrobial activity, TLR modulation, chemokine induction and regulation of phagocytosis. Sci Rep 7:40874.
https://doi.org/10.1038/srep40874 - Crimi E, Slutsky AS (2004) Inflammation and the acute respiratory distress syndrome. Best Pract Res Clin Anaesthesiol 18:477–492.
https://doi.org/10.1016/j.bpa.2003.12.007 - Cutuli SL, Ferrando ES, Cammarota F et al. (2024) Update on vitamin D role in severe infections and sepsis. J Anesth Analg Crit Care 4:4.
https://doi.org/10.1186/s44158-024-00139-5 - Delrue C, Speeckaert R, Delanghe JR et al. (2023) Vitamin D deficiency: An underestimated factor in sepsis? Int J Mol Sci 24:2924.
https://doi.org/10.3390/ijms24032924 - Dickson K, Lehmann C (2019) Inflammatory response to different toxins in experimental sepsis models. Int J Mol Sci 20:4341.
https://doi.org/10.3390/ijms20184341 - Dolin HH, Papadimos TJ, Chen X et al. (2019) Characterization of pathogenic sepsis etiologies and patient profiles: A novel approach to triage and treatment. Microbiol Insights 12:1178636118825081.
https://doi.org/10.1177/1178636118825081 - Dolmatova EV, Wang K, Mandavilli R et al. (2021) The effects of sepsis on endothelium and clinical implications. Cardiovasc Res 117:60–73.
https://doi.org/10.1093/cvr/cvaa070 - Duggan S, Leonhardt I, Hünniger K et al. (2015) Host response to Candida albicans bloodstream infection and sepsis. Virulence 6:316–326.
https://doi.org/10.4161/21505594.2014.988096 - Durnaś B, Wnorowska U, Pogoda K et al. (2016) Candidacidal activity of selected ceragenins and human cathelicidin LL-37 in experimental settings mimicking infection sites. PLoS One 11:e0157242.
https://doi.org/10.1371/journal.pone.0157242 - Elssner A, Duncan M, Gavrilin M et al. (2004) A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1β processing and release1. J Immunol 172:4987–4994.
https://doi.org/10.4049/jimmunol.172.8.4987 - Engelberg Y, Landau M (2020) The human LL-37(17-29) antimicrobial peptide reveals a functional supramolecular structure. Nat Commun 11:3894.
https://doi.org/10.1038/s41467-020-17736-x - Fukumoto K, Nagaoka I, Yamataka A et al. (2005) Effect of antibacterial cathelicidin peptide CAP18/LL-37 on sepsis in neonatal rats. Pediatr Surg Int 21:20–24.
https://doi.org/10.1007/s00383-004-1256-x - Gauer R, Forbes D, Boyer N (2020) Sepsis: Diagnosis and management. Am Fam Physician 101:409–418.
- Geitani R, Ayoub Moubareck C, Touqui L et al. (2019) Cationic antimicrobial peptides: Alternatives and/or adjuvants to antibiotics active against methicillin-resistant Staphylococcus aureus and multidrug-resistant Pseudomonas aeruginosa. BMC Microbiol 19:54.
https://doi.org/10.1186/s12866-019-1416-8 - Grondman I, Pirvu A, Riza A et al. (2020) Biomarkers of inflammation and the etiology of sepsis. Biochem Soc Trans 48:1–14.
https://doi.org/10.1042/bst20190029 - Guan J, Shichen M, Liang Z et al. (2023) Potential benefits of vitamin D for sepsis prophylaxis in critical ill patients. Front Nutr 10:1073894.
https://doi.org/10.3389/fnut.2023.1073894 - Guilhelmelli F, Vilela N, Albuquerque P et al. (2013) Antibiotic development challenges: The various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front Microbiol 4:353.
https://doi.org/10.3389/fmicb.2013.00353 - Guo W, Wang C, Huo F et al. (2018) [Evaluation value of human antibacterial peptide LL-37 on the prognosis of elderly patients with sepsis]. Zhonghua wei zhong bing ji jiu yi xue 30:1011–1016.
https://doi.org/10.3760/cma.j.issn.2095-4352.2018.011.001 - Holmes CL, Anderson MT, Mobley HLT et al. (2021) Pathogenesis of Gram-negative bacteremia. Clin Microbiol Rev 34:e00234–20.
https://doi.org/10.1128/CMR.00234-20 - Holt AM, Nett JE (2024) Innate immune response to Candida auris. Curr Opin Microbiol 80:102510.
https://doi.org/10.1016/j.mib.2024.102510 - Huang M, Cai S, Su J (2019) The pathogenesis of sepsis and potential therapeutic targets. Int J Mol Sci 20:5376.
https://doi.org/10.3390/ijms20215376 - Hu Z, Murakami T, Suzuki K et al. (2014) Antimicrobial cathelicidin peptide LL-37 inhibits the LPS/ATP-induced pyroptosis of macrophages by dual mechanism. PLoS One 9:e85765.
https://doi.org/10.1371/journal.pone.0085765 - Hu Z, Murakami T, Suzuki K et al. (2016) Antimicrobial cathelicidin peptide LL-37 inhibits the pyroptosis of macrophages and improves the survival of polybacterial septic mice. Int Immunol 28:245–253.
https://doi.org/10.1093/intimm/dxv113 - Hu Z, Nagaoka I (2016) Modulation of macrophage cell death, pyroptosis by host defense peptide LL-37. Juntendo Med J 62:98–104.
https://doi.org/10.14789/jmj.62.98 - Ince C, Mayeux PR, Nguyen T et al. (2016) The endothelium in sepsis. Shock 45:259–270.
https://doi.org/10.1097/shk.0000000000000473 - Jedynak M, Siemiątkowski A, Rygasiewicz K (2012) [Molecular basics of sepsis developemen]. Anestezjol Intens Ter 44: 248–252.
https://www.termedia.pl/Molecular-basics-of-sepsis &doubt;developement,144,39357,1,1.html - Jeng L, Yamshchikov AV, Judd SE et al. (2009) Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 7:28.
https://doi.org/10.1186/1479-5876-7-28 - Kahlenberg JM, Carmona-Rivera C, Smith CK et al. (2013) Neutrophil extracellular trap–associated protein activation of the NLRP3 inflammasome is enhanced in lupus macrophages. J Immunol 190:1217–1226.
https://doi.org/10.4049/jimmunol.1202388 - Koczulla R, von Degenfeld G, Kupatt C et al. (2003) An angiogenic role for the human peptide antibiotic LL-37/hCAP-18. J Clin Invest 111:1665–1672.
https://doi.org/10.1172/jci17545 - Koppen BC, Mulder PPG, de Boer L et al. (2019) Synergistic microbicidal effect of cationic antimicrobial peptides and teicoplanin against planktonic and biofilm-encased Staphylococcus aureus. Int J Antimicrob Agents 53:143–151.
https://doi.org/10.1016/j.ijantimicag.2018.10.002 - Koziel J, Bryzek D, Sroka A et al. (2014) Citrullination alters immunomodulatory function of LL-37 essential for prevention of endotoxin-induced sepsis. J Immunol 192:5363–5372.
https://doi.org/10.4049/jimmunol.1303062 - Kumagai Y, Murakami T, Kuwahara-Arai et al. (2020) Antimicrobial peptide LL-37 ameliorates a murine sepsis model via the induction of microvesicle release from neutrophils. Innate Immun 26:565–579.
https://doi.org/10.1177/1753425920936754 - Leite ML, Duque HM, Rodrigues GR et al. (2023) The LL-37 domain: A clue to cathelicidin immunomodulatory response? Peptides 165:171011.
https://doi.org/10.1016/j.peptides.2023.171011 - Lepper PM, Held TK, Schneider EM et al. (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Med 28:824–833.
https://doi.org/10.1007/s00134-002-1330-6 - Leszczyńska K, Namiot A, Janmey PA et al. (2010) Modulation of exogenous antibiotic activity by host cathelicidin LL-37. APMIS 118:830–836.
https://doi.org/10.1111/j.1600-0463.2010.02667.x - Li Z, Song Y, Yuan P et al. (2020) Antibacterial fusion protein BPI21/LL-37 modification enhances the therapeutic efficacy of hUC-MSCs in sepsis. Mol Ther 28:1806–1817.
https://doi.org/10.1016/j.ymthe.2020.05.014 - Liu A, Zhou Y, Ye P et al. (2019) [Clinical significance of antibacterial peptide LL-37 in early diagnosis of patients with sepsis in emergency department]. Zhonghua wei zhong bing ji jiu yi xue 31:1083–1086.
https://doi.org/10.3760/cma.j.issn.2095-4352.2019.09.005 - Majewski K, Kozłowska E, Żelechowska P et al. (2018) Serum concentrations of antimicrobial peptide cathelicidin LL-37 in patients with bacterial lung infections. Cent Eur J Immunol 43:453–457.
https://doi.org/10.5114/ceji.2018.81355 - Makowska M, Prahl A, Małuch I (2019) [Characteristic of AMP and the effects of chemical modifications on the modulation of their antimicrobial properties]. Postepy Biochem 65:278–288.
https://doi.org/10.18388/pb.2019_280 - Marturano JE, Lowery TJ (2019) ESKAPE pathogens in bloodstream infections are associated with higher cost and mortality but can be predicted using diagnoses upon admission. Open Forum Infect Dis 6:ofz503.
https://doi.org/10.1093/ofid/ofz503 - McMullan RR, McAuley DF, O’Kane CM et al. (2024) Vascular leak in sepsis: Physiological basis and potential therapeutic advances. Crit Care 28:97.
https://doi.org/10.1186/s13054-024-04875-6 - Memariani M, Memariani H (2023) Antifungal properties of cathelicidin LL-37: Current knowledge and future research directions. World J Microbiol Biotechnol 40:34.
https://doi.org/10.1007/s11274-023-03852-5 - Miao J, Ren Z, Zhong Z et al. (2022) The correlation of antibacterial peptides concentration in umbilical cord blood and early onset sepsis in preterm infants. Front Pediatr 10:903319.
https://doi.org/10.3389/fped.2022.903319 - Minasyan H (2019) Sepsis: Mechanisms of bacterial injury to the patient. Scand J Trauma Resusc Emerg Med 27:19.
https://doi.org/10.1186/s13049-019-0596-4 - Mookherjee N, Brown KL, Bowdish DM (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455–2464.
https://doi.org/10.4049/jimmunol.176.4.2455 - Morroni G, Sante LD, Simonetti O et al. (2021) Synergistic effect of antimicrobial peptide LL-37 and colistin combination against multidrug-resistant Escherichia coli isolates. Future Microbiol 16:221–227.
https://doi.org/10.2217/fmb-2020-0204 - Nagaoka I, Tamura H, Hirata M (2006) An antimicrobial cathelicidin peptide, human CAP18/LL-37, suppresses neutrophil apoptosis via the activation of formyl-peptide receptor-like 1 and P2X71. J Immunol 176:3044–3052.
https://doi.org/10.4049/jimmunol.176.5.3044 - Nagaoka I, Tamura H, Reich J (2020) Therapeutic potential of cathelicidin peptide LL-37, an antimicrobial agent, in a murine sepsis model. Int J Mol Sci 21:5973.
https://doi.org/10.3390/ijms21175973 - Nilsson BO (2020) What can we learn about functional importance of human antimicrobial peptide LL-37 in the oral environment from severe congenital neutropenia (Kostmann disease)? Peptides 128:170311.
https://doi.org/10.1016/j.peptides.2020.170311 - Ou Q, Tan L, Shao Y et al. (2022) Electrostatic charge-mediated apoptotic vesicle biodistribution attenuates sepsis by switching neutrophil NETosis to apoptosis. Small 18:2200306.
https://doi.org/10.1002/smll.202200306 - Pahar B, Madonna S, Das A et al. (2020) Immunomodulatory role of the antimicrobial LL-37 peptide in autoimmune diseases and viral infections. Vaccines (Basel) 8:517.
https://www.mdpi.com/2076-393X/8/3/517 .https://doi.org/10.3390/vaccines8030517 - Pavelka A, Vacek L, Norek A et al. (2024) Recombinant production of human antimicrobial peptide LL-37 and its secondary structure. Biologia 79:263–273.
https://doi.org/10.1007/s11756-023-01539-8 - Perez-Rodriguez A, Eraso E, Quindós G et al. (2022) Antimicrobial peptides with anti-candida activity. Int J Mol Sci 23:9264.
https://doi.org/10.3390/ijms23169264 - Popescu NI, Lupu C, Lupu F (2022) Disseminated intravascular coagulation and its immune mechanisms. Blood 139:1973–1986.
https://doi.org/10.1182/blood.2020007208 - Qin X, Zhu G, Huang L et al. (2019) LL-37 and its analog FF/CAP18 attenuate neutrophil migration in sepsis-induced acute lung injury. J Cell Biochem 120:4863–4871.
https://doi.org/10.1002/jcb.27641 - Quraishi SA, De Pascale G, Needleman JS et al. (2015) Effect of cholecalciferol supplementation on vitamin D status and cathelicidin levels in sepsis. Crit Care Med 43:1928–1937.
https://doi.org/10.1097/ccm.0000000000001148 - Rapala-Kozik M, Bochenska O, Zawrotniak M et al. (2015) Inactivation of the antifungal and immunomodulatory properties of human cathelicidin LL-37 by aspartic proteases produced by the pathogenic yeast Candida albicans. Infect Immun 83:2518–2530.
https://doi.org/10.1128/iai.00023-15 - Rather IA, Sabir JSM, Asseri AH et al. (2022) Antifungal activity of human cathelicidin LL-37, a membrane disrupting peptide, by triggering oxidative stress and cell cycle arrest in Candida auris. J Fungi (Basel) 8:204.
https://doi.org/10.3390/jof8020204 - Ridyard KE, Elsawy M, Mattrasingh D et al. (2023) Synergy between human peptide LL-37 and polymyxin B against planktonic and biofilm cells of Escherichia coli and Pseudomonas aeruginosa. Antibiotics (Basel) 12:389.
https://doi.org/10.3390/antibiotics12020389 - Ridyard KE, Overhage J (2021) The potential of human peptide LL-37 as an antimicrobial and anti-biofilm agent. Antibiotics (Basel) 10:650.
https://doi.org/10.3390/antibiotics10060650 - Salamah MF, Ravishankar D, Kodji X et al. (2018) The endogenous antimicrobial cathelicidin LL37 induces platelet activation and augments thrombus formation. Blood Adv 2:2973–2985.
https://doi.org/10.1182/bloodadvances.2018021758 - Sánchez-Peña FJ, Romero-Tlalolini M, Torres-Aguilar H et al. (2023) LL-37 triggers antimicrobial activity in human platelets. Int J Mol Sci 24:2816.
https://doi.org/10.3390/ijms24032816 - Scarsini M, Tomasinsig L, Arzese A et al. (2015) Antifungal activity of cathelicidin peptides against planktonic and biofilm cultures of Candida species isolated from vaginal infections. Peptides 71:211–221.
https://doi.org/10.1016/j.peptides.2015.07.023 - Scheenstra MR, van Harten RM, Veldhuizen EJA et al. (2020) Cathelicidins modulate TLR-activation and inflammation. Front Immunol 11:1137.
https://doi.org/10.3389/fimmu.2020.01137 - Shawky NM, EL-Antouny NG, Hassaan NK et al. (2022) Emerging relationship between vitamin D and LL-37 in the immune system’s response to infection and their possible role in combating sepsis. Egypt J Hosp Med 86:427–430.
https://doi.org/10.21608/ejhm.2022.213785 - Su W, Chen Y, Wang C et al. (2016) Human cathelicidin LL-37 inhibits platelet aggregation and thrombosis via Src/PI3K/Akt signaling. Biochem Biophys Res Commun 473:283–289.
https://doi.org/10.1016/j.bbrc.2016.03.095 - Sun W, Zheng Y, Lu Z et al. (2014) LL-37 attenuates inflammatory impairment via mTOR signaling-dependent mitochondrial protection. Int J Biochem Cell Biol 54:26–35.
https://doi.org/10.1016/j.biocel.2014.06.015 - Suzuki K, Murakami T, Kuwahara-Arai K et al. (2011) Human anti-microbial cathelicidin peptide LL-37 suppresses the LPS-induced apoptosis of endothelial cells. Int Immunol 23:185–193.
https://doi.org/10.1093/intimm/dxq471 - Szulcek R, Bollensdorff C, Hordijk P et al. (2018) The covalently immobilized antimicrobial peptide LL37 acts as a VEGF mimic and stimulates endothelial cell proliferation. Biochem Biophys Res Commun 496:887–890.
https://doi.org/10.1016/j.bbrc.2018.01.130 - Turner J, Cho Y, Dinh NN et al. (1998) Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother 42:2206–2214.
https://doi.org/10.1128/aac.42.9.2206 - Vaishnavi C (2013) Translocation of gut flora and its role in sepsis. Indian J Med Microbiol 31:334–342.
https://doi.org/10.4103/0255-0857.118870 - van der Poll T, Shankar-Hari M, Wiersinga W (2021) The immunology of sepsis. Immunity 54:2450–2464.
https://doi.org/10.1016/j.immuni.2021.10.012 - Vandamme D, Landuyt B, Luyten W et al. (2012) A comprehensive summary of LL-37, the factotum human cathelicidin peptide. Cell Immunol 280:22–35.
https://doi.org/10.1016/j.cellimm.2012.11.009 - Vardon-Bounes F, Ruiz S, Gratacap MP et al. (2019) Platelets are critical key players in sepsis. Int J Mol Sci 20:3494.
https://doi.org/10.3390/ijms20143494 - Wang G (2008) Structures of human host defense cathelicidin LL-37 and its smallest antimicrobial peptide KR-12 in lipid micelles. J Biol Chem 283:32637–32643.
https://doi.org/10.1074/jbc.M805533200 - Wang Q, Wen W, Zhou L et al. (2024) LL-37 improves sepsis-induced acute lung injury by suppressing pyroptosis in alveolar epithelial cells. Int Immunopharmacol 129:111580.
https://doi.org/10.1016/j.intimp.2024.111580 - Wiersinga WJ, van der Poll T (2022) Immunopathophysiology of human sepsis. EBioMedicine 86:104363.
https://doi.org/10.1016/j.ebiom.2022.104363 - Xhindoli D, Pacor S, Benincasa M et al. (2016) The human cathelicidin LL-37 – A pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta 1858:546–566.
https://doi.org/10.1016/j.bbamem.2015.11.003 - Xiong Y, Hla T (2014) S1P control of endothelial integrity. Curr Top Microbiol Immunol 378:85–105.
https://doi.org/10.1007/978-3-319-05879-5_4 - Xue W, Pang J, Liu J et al. (2022) Septic cardiomyopathy: Characteristics, evaluation, and mechanism. Emerg Crit Care Med 2:135–147.
https://doi.org/10.1097/EC9.0000000000000060 - Yanagisawa T, Ishii M, Takahashi M et al. (2020) Human cathelicidin antimicrobial peptide LL-37 promotes lymphangiogenesis in lymphatic endothelial cells through the ERK and Akt signaling pathways. Mol Biol Rep 47:6841–6854.
https://doi.org/10.1007/s11033-020-05741-8 - Yang D, Chen Q, Schmidt AP et al. (2000) LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med 192:1069–1074.
https://doi.org/10.1084/jem.192.7.1069 - Yang B, Good D, Mosaiab T et al. (2020) Significance of LL-37 on immunomodulation and disease outcome. Biomed Res Int 2020:8349712.
https://doi.org/10.1155/2020/8349712 - Zeth K, Sancho-Vaello E (2021) Structural plasticity of LL-37 indicates elaborate functional adaptation mechanisms to bacterial target structures. Int J Mol Sci 22:5200.
https://www.mdpi.com/1422-0067/22/10/5200 .https://doi.org/10.3390/ijms22105200 - Zhu C, Liang Y, Luo Y et al. (2023) Role of pyroptosis in hemostasis activation in sepsis. Front Immunol 14:1114917.
https://doi.org/10.3389/fimmu.2023.1114917